Data monetization is no longer an option—it's a necessity. In the life sciences sector, data is a strategic asset that can drive business growth and innovation. Our comprehensive report explores how life sciences companies can monetize their data through key strategies.
What you'll learn:
- The value of embracing data as a true corporate asset
- How to track and measure the value of your data to position your organization for success
- How to utilize our BOWS framework to ensure you are maximizing your data’s potential
- Examples from across industries showing how companies are successfully monetizing their data
Data is a unique asset with the power to transform your business. By adopting strategic data monetization practices, life sciences companies can unlock new value and drive sustainable growth.
Ready to turn your data into a powerhouse of profitability? Download our comprehensive report, "Data Monetization in Life Sciences," and start your journey towards unlocking unprecedented value from your data today.
Download the Report
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
